STOCK TITAN
  1. Home
  2. News
  3. NRXP

NRX Pharmaceuticals, Inc. - $NRXP STOCK NEWS

Welcome to our dedicated page for NRX Pharmaceuticals news (Ticker: $NRXP), a resource for investors and traders seeking the latest updates and insights on NRX Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NRX Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NRX Pharmaceuticals's position in the market.

News
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announced significant milestones for 2024, including clinical trial data, NDA filing, share dividend, and commercial revenue forecasts. The company reported a 50% reduction in corporate overhead, 25% reduction in net loss, and an improvement in negative earnings per share. Key partnerships and advancements in NRX-101 development for bipolar depression, chronic pain, and urinary tract infection were highlighted. The company also established HOPE Therapeutics for IV Ketamine, with positive financial results and working capital additions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1012.52%
Tags
earnings
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces anticipated financial results for FY 2023, highlighting improved negative EPS, positive cash flow projections by 2024, reduction in corporate indebtedness, key partnerships with Alvogen and Lotus Pharmaceuticals, successful clinical trial data for NRX-101 in bipolar depression, positive outcomes in ketamine studies, and plans for NDA filings and share dividends.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
earnings
-
News
NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will undergo a reverse stock split on April 1, 2024, where every 10 pre-split shares will convert to 1 post-split share. The split-adjusted common stock will trade under the symbol NRXP on the Nasdaq Capital Market starting April 2, 2024. The reverse split aims to align share price with institutional investor preferences and enhance long-term shareholder value. Positive clinical trial data and future developments indicate potential for a forward stock split.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.96%
Tags
stock split
News
UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) to release Q4 and full year 2023 financial results on March 28, 2024. Conference call rescheduled to April 1, 2024, due to Good Friday holiday. Webcast and dial-in options available for participation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
conferences earnings
-
News
NRx Pharmaceutical's (NASDAQ:NRXP) Chairman Dr. Jonathan Javitt to Present at the Ketamine 2024 Conference in Oxford, UK
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) announced Dr. Jonathan Javitt will present at the Ketamine 2024 Conference in Oxford, UK. The conference gathers leading scientists and clinicians worldwide to share knowledge and insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
conferences
-
News
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Corporate Update on March 28, 2024
Rhea-AI Summary
NRx Pharmaceuticals, Inc. (NRXP) will release its Q4 and full year 2023 financial results on March 28, 2024. A conference call to discuss the results and provide a corporate update will be held at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.87%
Tags
conferences earnings
News
NRx Pharmaceuticals Announces Results of the Vote Held During the Special Meeting of Shareholders
Rhea-AI Summary
NRx Pharmaceuticals, Inc. announces the results of a Special Meeting of Shareholders with 61.4% of eligible shares voted, 94.4% in favor of a proposal for a reverse stock split. Despite efforts to suppress the vote, shareholders showed overwhelming support for the resolution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.14%
Tags
none
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Plan to Distribute Shares of HOPE Therapeutics and Royalty Rights on Ketamine Sales to Existing NRx Shareholders
Rhea-AI Summary
NRx Pharmaceuticals authorizes Dividend and Royalty Rights to NRXP Shareholders and warrant holders, distributing 49% of HOPE Therapeutics stock and 1% of Ketamine sales. Proxy voting for special meeting on March 21, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.16%
Tags
none
-
News
NRx Pharmaceuticals (NASDAQ:NRXP) Initiates Strategy to Combat Short Sales
Rhea-AI Summary
NRx Pharmaceuticals, Inc. takes action to protect shareholder value by addressing short sellers through proposed changes in corporate name, CUSIP number, and potential reverse split. The Company aims to ensure compliance with Nasdaq listing rules and prevent naked short sales positions in its securities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-34.32%
Tags
none
News
NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)
Rhea-AI Summary
NRx Pharmaceuticals and HOPE Therapeutics partner with Conversio Health and Nephron Pharmaceuticals to provide IV Ketamine to patients and clinics, aiming to offer high-quality solutions and ensure ongoing supply. The Company is set to receive its first allocation of ketamine by the end of March 2024, with plans to commence sales once technical aspects are finalized.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.06%
Tags
none
Stock NRXP logo
NRX Pharmaceuticals, Inc.

Nasdaq:NRXP

NRXP Rankings

#4995 Ranked by Market Cap
#4956 Ranked by Stock Gains
N/A Ranked by Dividends

NRXP Stock Data

30.93M
6.63M
30.04%
4.29%
4.44%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WILMINGTON